Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on GoodRx Holdings, Lowers Price Target to $12

Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $15 to $12.
byBenzinga Newsdesk
July 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $15 to $12.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Republic Bank Has Been Notified By The Listing Qualifications Department Of The Nasdaq That, As Of August 23, The Co’s Stock Will No Longer Be Listed On The Exchange Because The Company Has Not Filed Its Annual Report On Form 10-K With The SEC For FY22

By Happy Mohamed
August 22, 9:44 AM
Republic First Bancorp, Inc. (NASDAQ:FRBK) ("Republic" or the "Company"), the parent company of Republic First Bank d/b/a Republic Bank, today announced that it has been notified by the Listing

FRBK